| scholarly article | Q13442814 |
| P50 | author | Olivier Lortholary | Q30089934 |
| David W. Denning | Q30533462 | ||
| Raoul Herbrecht | Q37841047 | ||
| Thomas F Patterson | Q56859142 | ||
| John R Wingard | Q57012166 | ||
| Helen Boucher | Q84806071 | ||
| Patricia Ribaud | Q114324338 | ||
| Haran T Schlamm | Q114412692 | ||
| Peter F Troke | Q114412697 | ||
| P2093 | author name string | Robert H Rubin | |
| John E Bennett | |||
| Ben DePauw | |||
| European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG) | |||
| Pfizer Global Aspergillus Study Group | |||
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. | Q34143326 | ||
| Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. | Q35746695 | ||
| A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients | Q40577742 | ||
| Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 | ||
| Amphotericin B: time for a new "gold standard". | Q44527998 | ||
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 | ||
| The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis | Q45179704 | ||
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| amphotericin B | Q412223 | ||
| voriconazole | Q412236 | ||
| invasive aspergillosis | Q3625278 | ||
| invasion impact | Q112148709 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1448-1452 | |
| P577 | publication date | 2005-10-13 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome | |
| P478 | volume | 41 |
| Q59429682 | 2-Heteroaryl-[1,2,4]triazolo[1,5-c]quinazoline-5(6 H)-thiones and Their S-Substituted Derivatives: Synthesis, Spectroscopic Data, and Biological Activity |
| Q35942379 | An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole |
| Q37916822 | Antifungal therapy |
| Q41653776 | Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization |
| Q34637909 | Aspergillus fumigatus AcuM regulates both iron acquisition and gluconeogenesis |
| Q39199167 | Assessment Techniques to Detect Aspergillus fumigatus in Different Samples of Immunosuppressed Male Western Albino Rats |
| Q64070463 | Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B |
| Q38102782 | Combination antifungal therapy for invasive fungal infections in children and adults |
| Q37079099 | Current and future therapeutic options in the management of invasive aspergillosis |
| Q37164085 | Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria |
| Q36295480 | Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy |
| Q37944001 | Efficacy and safety of current drug therapies for invasive aspergillosis |
| Q37123394 | Fungicidal versus Fungistatic: what's in a word? |
| Q37263430 | Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q58376545 | Invasive fungal sinusitis: An effective combined treatment in five haematological patients |
| Q37202860 | Management of fungal infections following allogeneic stem cell transplantation |
| Q46840248 | Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin |
| Q37929788 | Opportunistic fungal infections in the Asia-Pacific region |
| Q37790947 | Pediatric Invasive Aspergillosis |
| Q37892536 | Pharmacogenomics of the triazole antifungal agent voriconazole |
| Q37662650 | Safety of triazole antifungal drugs in patients with cancer |
| Q34543970 | Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis |
| Q37327086 | Sequential prescription of antifungals in invasive fungal infection: the importance of mechanism of action |
| Q33876645 | Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. |
| Q79300230 | The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida |
| Q34357504 | Treatment options in Invasive Aspergillosis |
| Q61832641 | Update on invasive fungal infections: the last two years |
| Q37767359 | Use of Antifungal Combination Therapy: Agents, Order, and Timing |
| Q90623202 | Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study |
| Q28540254 | Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis |
| Q40189236 | Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections |
| Q91907661 | [Infections as oncologic emergencies] |
| Q93165640 | [Infections as oncologic emergencies] |
Search more.